Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy

NEW YORK--(BUSINESS WIRE)--Jun 12, 2024--

Related Keywords

Dan Levy ,Pfizer Inc ,Pfizer ,Development Head For Duchenne ,Exchange Commission ,Linkedin ,Fordadistrogene Movaparvovec Clinical Program ,Youtube ,North Star Ambulatory Assessment ,Development Head ,Fordadistrogene Movaparvovec Clinical ,Breakthroughs That Change Patient ,Pfizer News ,Annual Report ,Looking Information ,Factors That May Affect Future ,Orphanetj Rare ,Business Wire ,